ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 144 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $144,741 | -84.4% | 12,958 | -70.2% | 0.00% | – |
| Q2 2023 | $930,793 | +123.2% | 43,495 | +321.8% | 0.00% | – |
| Q1 2023 | $417,018 | -76.4% | 10,312 | -72.9% | 0.00% | -100.0% |
| Q4 2022 | $1,768,504 | +1465.0% | 38,016 | +1645.5% | 0.00% | – |
| Q3 2022 | $113,000 | -80.4% | 2,178 | -82.1% | 0.00% | – |
| Q2 2022 | $576,000 | -68.0% | 12,179 | -51.9% | 0.00% | -100.0% |
| Q1 2022 | $1,801,000 | -40.3% | 25,304 | -37.3% | 0.00% | 0.0% |
| Q4 2021 | $3,018,000 | +70.3% | 40,364 | +29.4% | 0.00% | 0.0% |
| Q3 2021 | $1,772,000 | +265.4% | 31,205 | +183.3% | 0.00% | – |
| Q2 2021 | $485,000 | -62.5% | 11,014 | -58.0% | 0.00% | – |
| Q1 2021 | $1,294,000 | +32250.0% | 26,230 | +27804.3% | 0.00% | – |
| Q4 2020 | $4,000 | -82.6% | 94 | -79.4% | 0.00% | – |
| Q2 2020 | $23,000 | -90.9% | 456 | -90.7% | 0.00% | – |
| Q1 2020 | $252,000 | -30.8% | 4,903 | -16.8% | 0.00% | – |
| Q4 2019 | $364,000 | -78.0% | 5,893 | -78.6% | 0.00% | -100.0% |
| Q3 2019 | $1,656,000 | +216.6% | 27,573 | +344.9% | 0.00% | – |
| Q2 2019 | $523,000 | +3923.1% | 6,197 | +4741.4% | 0.00% | – |
| Q1 2019 | $13,000 | -99.4% | 128 | -99.6% | 0.00% | -100.0% |
| Q4 2018 | $2,169,000 | +106.0% | 30,617 | +148.5% | 0.00% | – |
| Q3 2018 | $1,053,000 | +86.4% | 12,321 | +152.9% | 0.00% | – |
| Q2 2018 | $565,000 | -74.9% | 4,871 | -82.5% | 0.00% | -100.0% |
| Q1 2018 | $2,247,000 | +1757.0% | 27,769 | +1246.0% | 0.00% | – |
| Q4 2017 | $121,000 | -65.3% | 2,063 | -72.3% | 0.00% | – |
| Q3 2017 | $349,000 | +2808.3% | 7,446 | +2219.6% | 0.00% | – |
| Q2 2017 | $12,000 | +50.0% | 321 | +18.5% | 0.00% | – |
| Q1 2017 | $8,000 | -97.3% | 271 | -96.9% | 0.00% | – |
| Q4 2016 | $296,000 | +316.9% | 8,831 | +232.6% | 0.00% | – |
| Q3 2016 | $71,000 | -73.1% | 2,655 | -77.9% | 0.00% | – |
| Q2 2016 | $264,000 | +810.3% | 11,992 | +1112.5% | 0.00% | – |
| Q1 2016 | $29,000 | -96.8% | 989 | -96.4% | 0.00% | -100.0% |
| Q4 2015 | $912,000 | +253.5% | 27,629 | +287.6% | 0.00% | – |
| Q3 2015 | $258,000 | +1190.0% | 7,129 | +1523.9% | 0.00% | – |
| Q2 2015 | $20,000 | +122.2% | 439 | +46.3% | 0.00% | – |
| Q1 2015 | $9,000 | -97.6% | 300 | -96.0% | 0.00% | – |
| Q4 2014 | $379,000 | – | 7,450 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
| Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
| ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
| Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
| Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
| Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
| Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
| Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |